Serious Hypokalemia Associated with Abiraterone Acetate in Patients with Castration-Resistant Prostate Cancer

INTRODUCTION: The treatment strategy for castration-resistant prostate cancer (CRPC) has changed with the approval of several new agents. In 2011, abiraterone acetate was approved for the treatment of metastatic CRPC; however abiraterone is known to cause mineralocorticoid excess syndrome characteri...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamamoto, Yutaka, Akashi, Yasunori, Minami, Takahumi, Nozawa, Masahiro, Kiba, Keisuke, Yoshikawa, Motokiyo, Hirayama, Akihide, Uemura, Hirotsugu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165612/
https://www.ncbi.nlm.nih.gov/pubmed/30305978
http://dx.doi.org/10.1155/2018/1414395

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165612/
https://www.ncbi.nlm.nih.gov/pubmed/30305978
http://dx.doi.org/10.1155/2018/1414395

Ejemplares similares